

PROMOTION RECOMMENDATION
THE UNIVERSITY OF MICHIGAN
MEDICAL SCHOOL
DEPARTMENT OF INTERNAL MEDICINE

Douglas A. Arenberg, M.D., associate professor of internal medicine, with tenure, Department of Internal Medicine, Medical School, is recommended for promotion to professor of internal medicine, with tenure, Department of Internal Medicine, Medical School.

Academic Degrees:

M.D.	1990	University of Illinois, Chicago
B.S.	1986	Bioengineering, University of Illinois, Chicago

Professional Record:

2003-present	Associate Professor of Internal Medicine, University of Michigan
1997-2003	Assistant Professor of Internal Medicine, University of Michigan
1996-1997	Lecturer of Internal Medicine, University of Michigan

Summary of Evaluation:

Teaching: Dr. Arenberg is an active teacher of medical students, residents, fellows and faculty, within the classroom setting, inpatient service, outpatient clinics and through didactic lectures. He interacts with pre-med bioengineering students on a project in practical problem solving. Dr. Arenberg presents to first and second year medical students on the Respiratory Sequence and Lung Cancer. He also developed and teaches a tobacco cessation class to first year medical students. To further illuminate Dr. Arenberg's teaching impact, he was given the Teaching Award for Medical Students and has twice been given the Outstanding Teacher Award from division fellows. His teaching philosophy is to encourage increased assumption of responsibility by decision making in the face of uncertainty and his teaching evaluation feedback confirms students appreciate this approach. He is a member of the dissertation committee for two Ph.D. students in the School of Public Health and serves as mentor for several fellows and junior faculty. Dr. Arenberg's ultimate goal is to improve the lives of lung cancer patients. Through his gift for teaching, he transfers this passion to students and colleagues alike to build a strong foundation for the common goal. He is extensively involved in the American College of Chest Physicians the American Thoracic Society and the International Society for the Study of Lung Cancer. Within these platforms, Dr. Arenberg presents to a multitude of peer groups on topics of lung cancer and lung cancer screening.

Research: Dr. Arenberg is an expert in the diagnosis and management of lung cancer. His research interests are to define and validate biomarkers of lung cancer risk with a focus on quality improvement aimed to standardize and improve the care of patients with lung cancer across the spectrum from diagnosis and staging, to treatment and management of complications. He was accepted into the MICHR-based Patient Oriented Research Training (PORT) program, where he developed his current quality improvement/research project examining the impact of adherence to Evidence Based Guidelines. The PORT program provided a perfect supplement to his basic science background with fundamental clinical research skills, resulting in expertise that spans across basic science, clinical and translational science. This skill set combined with his expertise in lung cancer allows him to fill a unique niche in pulmonary and critical care medicine. As such, Dr. Arenberg is a highly sought after member of multidisciplinary teams needing expertise that straddles the basic and clinical solutions in the lung cancer field. He is frequently asked to collaborate in federally funded studies with colleagues

within and outside of the department. He has been awarded multiple NIH grants as the principal investigator, a K08 and an R01, several NIH grants as a co-investigator, an R01, R21, and N01, numerous foundation and industry-based grants and has received funding from the Michigan Department of Health and Human Services consecutively for the past five years for his Lung Cancer Screening and Tobacco Cessation study. His collaborations with Dr. Kazerooni in Radiology have led to his holding a sub project on her NIH grant entitled “Personalized Smoking Cessation Tool Based on Patient Lung CT Image.” Dr. Arenberg has published 95 peer-reviewed publications. He has embraced team science, as best reflected by his participation in network studies and society consensus statements. The quality of his research is outstanding, as reflected in the numerous times he has been asked to present his work at national and international meetings, including the International Association for the Study of Lung Cancer World Congress on Lung Cancer in Austria, and the annual American Thoracic Society International Conferences.

Recent and Significant Publications:

Mazzone PJ, Rufatto-Sears C, Arenberg DA, Gaga M, et. al., on behalf of the American Thoracic Society Assembly on Thoracic Oncology: Evaluating Molecular Biomarkers for the Early Detection of Lung Cancer: When Is a Biomarker Ready for Clinical Use? An Official American Thoracic Society Policy Statement. *AJRCCM* 196(7), 2017.

Detterbeck FC, Bolejack V, Arenberg DA, Crowley J, Donington JS, Franklin WA, Girard N, Marom EM, Mazzone PJ, Nicholson AG, Rusch VW, Tanoue LT, Travis WD, Asamura H, et. al. The IASLC Lung Cancer Staging Project: Background Data and Proposals for the Classification of Lung Cancer with Separate Tumor Nodules in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. *J Thorac Oncol.* May;11(5):681-92, 2016.

Wiener RS, Gould MK, Arenberg DA, Au DH, Fennig K, Lamb CR, Mazzone P, Midthun DE, Napoli M, Ost DE, Powell CA, Rivera P, Slatore CG, Tanner NT, Vachani A, Wisnivesky JP, Yoon SH: Writing Committee: Official American Thoracic Society / American College of Chest Physicians. Official American Thoracic Society / American College of Chest Physicians Policy Statement: Implementation of Lung Cancer Screening Programs with Low-Dose Computed Tomography in Clinical Practice. *Am J Respir Crit Care Med* 192(7), pp. 881-891, 2015.

Ramnath N, Dilling T, Harris L, Kim A, Michaud G, Balekian A, Detterbeck F, Diekemper R, Arenberg DA: American College of Chest Physicians: Diagnosis and Management of Lung Cancer: Treatment of Stage III Non-Small Cell Lung Cancer. ACCP Evidence-based Clinical Practice Guidelines (3rd Edition). *Chest.* May;143(5 Suppl), 2013.

Arenberg DA, McMillan T, Carskadon SL, Zhao L, Amin M, Koch AE: Macrophage Migration Inhibitory Factor Promotes Tumor Growth in the Context of Lung Injury and Repair. *Am J Respir Crit Care Med.* 15;182(8):1030-1037, 2010.

Service: Dr. Arenberg’s clinical interests are in the early detection, diagnosis and staging of lung cancer. He sees patients in the multidisciplinary thoracic oncology clinic where he focuses on the evaluation of patients with suspected lung cancer. He is the director of the Lung Cancer Screening Program and Bronchoscopy Services. In recognition of his esteemed reputation, Dr. Arenberg was recently appointed to the University of Michigan Medical School Executive Committee for Clinical Affairs and the Medical School Advisory Committee on Appointments, Promotions and Tenure. He also serves as the co-chair for the Michigan Medicine Tobacco Treatment Strategy Group. Dr. Arenberg participates in the Michigan Department of Public Health Cancer Consortium: Early

Detection Working Group. He has been a member of the American College of Clinical Pathology since 2005, serving as the vice chair (2008-2010) and chair (2010-2012) of the Thoracic Oncology Network and as an editor of the Evidence Based Lung Cancer Guidelines (2010-2012). Dr. Arenberg has been an active member of American Thoracic Society since 2008, serving on the task force groups for Respiratory Cell, Molecular Biology, and Lung Cancer. He serves as a member of Thoracic Oncology Executive Committee, was nominated to chair this committee from 2014-2015 and most recently was selected to serve on the Nominating Committee (2018-2020). He serves as a member on the International Association for the Study of Lung Cancer: Tobacco Control and Smoking Cessation Committee and the Multiple Pulmonary Tumor Sites Workgroup. Dr. Arenberg serves on several study sections and editorial boards including as an associate editor for *Respiratory Medicine*. It is clear that Dr. Arenberg is engaged and dedicated to his profession on a broad spectrum.

External Reviewers:

Reviewer A: “Doug is a highly valued colleague with a national reputation for excellence in the field of thoracic oncology, and one of the nation’s premier ‘interventional onco-pulmonologists,’ as he has been known to self-identify...I was thrilled when he accepted my invitation to serve as a member of the Data Safety Monitoring Board for the Watch the Spot trial, a PCORI-funded, \$14M pragmatic clinical trial...Doug is clearly in the top 10% when compared with peers who aspire to ‘triple treat’ status as clinical-educator-investigators...his credentials would easily meet criteria for promotion at the academic institutions where I worked previously...”

Reviewer B: “...he can convey complex concepts to diverse audiences in a welcoming, humble, and engaging manner that results in new understanding that learners of all levels appreciate...he has an invaluable basic science background...which is a rare credential among pulmonary clinical scientist leaders in the lung cancer field...Dr. Arenberg was inducted into the Department of Internal Medicine Clinical Excellence Society. His national reputation and service to his academic health center are undeniable, and I believe his trajectory for future recognition is steep. I can categorically state that he would easily be approved for promotion to Professor at [my institution].”

Reviewer C: “Douglas was Chair of the Program Committee during my tenure as Chair of the Assembly and his efforts were noteworthy and key to the eventual success of the Assembly... Dr. Arenberg is a nationally recognized thought leader in lung cancer. His publications on lung cancer screening, diagnosis and treatment have contributed meaningfully to important advances in lung cancer science and clinical care.”

Reviewer D: “He has been a vital force in all the major efforts advancing the clinical evaluation and management of patients with lung cancer and I am cognizant of his excellent reputation and contributions in the field of Thoracic Oncology...He has established himself as a regional, national and international expert and is an active participant, as chair and speaker, at multiple annual national and international meetings...His contributions to the thoracic oncology literature have been substantial and meaningful...This is a remarkable volume of work garnering respect from his peers and contributing to his reputation as a frontrunner within the Thoracic Oncology community... Dr. Arenberg meets all of the standards for promotion to Professor with Tenure at [my institution].”

Reviewer E: “Doug Arenberg does nothing that is not of the highest quality. He certainly would trade off quantity for quality. Despite that, he has 98 peer reviewed-publications...These publications are outstanding and represent the fact that Doug is clearly seen as a national and international expert, whose views are valued by multiple constituencies...The management of lung cancer practice guidelines have been downloaded more than 500,000 times since their publication in 2013...Dr.


Arenberg represents a dying breed of the triple threat in academics. He is an outstanding clinician, educator, and researcher.”

Reviewer F: “Dr. Arenberg’s publications have had a significant impact upon basic science and clinical investigation into lung cancer...Dr. Arenberg has also dedicated himself to teaching of medical students, medical residents, and pulmonary and critical care fellows, and has mentored several fellows and residents who have gone on to successful careers in academic medicine.”

Reviewer G: “...he sits on the Executive Committee for the American College of Chest Physicians Evidence-Based Lung Cancer Guidelines, which are recognized as among the most widely used international resources for lung cancer diagnosis and management...I would point out that three of the publications he identified as his core work have been instrumental in shaping clinical care in evolving domains...He is an asset to your institution...”

Summary of Recommendation:

Dr. Arenberg is recognized nationally and internationally as an expert in thoracic oncology. His expertise and knowledge qualify him as one of the best lung cancer specialists in the field of pulmonary and critical care. His ongoing collaborations with thoracic oncology and radiology will be impactful to Michigan Medicine in showcasing our institution as one of the best in the areas of lung cancer detection and smoking cessation. I am pleased to recommend Douglas A. Arenberg, M.D. for promotion to professor of internal medicine, with tenure, Department of Internal Medicine, Medical School.



Marschall A. Runge, M.D., Ph.D.
Executive Vice President for Medical Affairs
Dean, Medical School

May 2019